



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Lorigerlimab

Cat. No.:	HY-P99714
CAS No.:	2416595-46-3
Target:	PD-1/PD-L1; CTLA-4
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) ^{[1][2][3]} .								
In Vitro	Lorigerlimab (0.01 nM-1 nM) binds to Jurkat/PD-1 cells and blocks PD-L1 binding to the cells ^[2] . Lorigerlimab can independently engage and block PD-1 and CTLA-4 on cells expressing one or the other checkpoint molecule (EC ₅₀ : 0.42 nM for PD-1+ cells, 4.8 nM for CTLA-4+ cells, 0.013 nM for PD-1 and CTLA-4+ cells) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Lorigerlimab (75 mg/kg, i.v.) shows CTLA-4 blockade in in cynomolgus monkeys ^[2] . Lorigerlimab (10-100 mg/kg, i.v., 4 weeks) is well tolerated in cynomolgus monkeys, and shows a half-life about 7 days ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkeys ^[4]</td> </tr> <tr> <td>Dosage:</td> <td>75 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.</td> </tr> <tr> <td>Result:</td> <td>Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen.</td> </tr> </table>	Animal Model:	Cynomolgus monkeys ^[4]	Dosage:	75 mg/kg	Administration:	i.v.	Result:	Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen.
Animal Model:	Cynomolgus monkeys ^[4]								
Dosage:	75 mg/kg								
Administration:	i.v.								
Result:	Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen.								

REFERENCES

- [1]. Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort. *Journal of Clinical Oncology* 2023 41:6_suppl, 155-155.
- [2]. Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. *Cell Rep Med.* 2020 Dec 22;1(9):100163.
- [3]. Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. *Front Oncol.* 2021 Jun 10;11:670726.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA